Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany

PharmacoEconomics

Volumn 24, Issue SUPPL. 1, 2006, Pages 35-48

  Shearer, Arran T ^a,e   Bagust, Adrian ^a   Liebl, Andreas ^b   Schoeffski, Oliver ^c   Goertz, Anita ^d  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Centre for Diabetes and Metabolism   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d GLAXOSMITHKLINE   (Germany)

^e UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

AGE DISTRIBUTION; CLINICAL TRIAL; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE ASSOCIATION; FINANCIAL MANAGEMENT; GERMANY; HOSPITAL PATIENT; HUMAN; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SEX RATIO; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644994101     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624001-00004     Document Type: Review

References (40)

1. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-15
2. Erratum in Diabetes Care 2001; 24: 973
3. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84
4. International Diabetes Federation. Diabetes Atlas 2001. Brussels: International Diabetes Federation; 2001
5. Hauner H, Koster I, von Ferber L. Prevalence of diabetes mellitus in Germany 1998-2001. Secondary data analysis of a health insurance sample of the AOK in Hessen/KV in Hessen. Dtsch Med Wochenschr 2003; 128: 2631
6. Palitzsch KD, Nusser J, Arndt H, et al. Die Häufigkeit des Diabetes mellitus wird in Deutschland falsch eingeschätzt - ein gesundheitspolitisches und sozioökonomisches Problem [in German]. Diab Stoffw 1999; 8: 189-200
7. Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening: The KORA survey 2000. Diabetologia 2003; 46: 182-9
8. Klein R. Hyperglycaemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-68
9. Stevens RJ, Kothari V, Adler AI, et al. on behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes (UKDPS 56). Clin Sci 2001; 101: 671-9
10. Liebl A, Neiss A, Spannheimer A, et al. Complications, comorbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2 study. Exp Clin Endocrinol Diabetes 2002; 110: 10-6
11. Liebl A, Neiss A, Spannheimer A, et al. Costs of type 2 diabetes in Germany. Results of the CODE-2 study. Dtsch Med Wochenschr 2001; 126: 585-9
12. Bagust A, Hopkinson PK, Maier W, et al. An economic model of the long-term health care burden of type 2 diabetes. Diabetalogia 2001; 44: 2140-55
13. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2004; 7 September [Epub ahead of print]
14. Czoski-Murray C, Warren E, Chilcott J, et al. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technology Assessment 2004; v.8
15. Bagust A, Evans M, Beale S, et al. A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. Pharmacoeconomics 2006; 24 (Suppl. 1): 5-19
16. Statistisches Bundesamt. Statistical yearbook 2002 for the Federal Republic of Germany. Stuttgart: Metzler-Poeschel; 2002
17. National Diabetes Data Group. Diabetes in America. National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, NIH Publication No. 95-1468; 1995
18. Statistisches Bundesamt. Todesursachenstatistik [in German]. Stuttgart: Metzler-Poeschel; 2002
19. Statistisches Bundesamt. Fachserie 12, Reihe 6.2: Diagnosedaten der Krankenhauspatienten 1999 [in German]. Stuttgart: Metzler-Poeschel; 2001
20. Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy and ulceration in diabetes. Diabetes Care 1998; 21: 42-8
21. Carrl F, Aguilar M, Olveira G, et al. Increased hospital expenditures in diabetic patients hospitalized for cardiovascular diseases. J Diabet Complic 2003; 17: 331-6
22. Statistisches Bundesamt. Fachserie 12, Reihe 6.2: Diagnosedaten der Krankenhauspatienten 1999 (Special analysis) [in German]. Stuttgart: Metzler-Poeschel; 2001
23. Official PKV-Statistics. Specialty ward bed day costs; Germany 2001
24. Nebel M. Behandlungskosten der Nierenersatztherapie in Deutschland 1999 [in German]. Nieren- und Hochdruckkrankheiten 2002; 31: 85-92
25. IMS Health Gmbh & Co. IMS disease analyser: mediplus. Frankfurt: IMS Health GmbH & Co.; International Marketing Services 2002
26. Nink K, Schoeder H Der Arzneimittelmarkt in der Bundesrepublik Deutschland [in German]. In: Schwabe U, Pfaffrath D, editors. Arzneiverordnungs report 2002 - Aktuelle Daten, Kosten, Trends und Kommentare. Springer Verlag, Germany 2003
27. Scheil R, Muller UA, Sprott H, et al. The JEVIN-trial: a population-based survey on the quality of diabetes care in Germany: 1994/1995 compared to 1989/1990. Diabetalogia 1997; 40: 1350-7
28. Deutsche Diabetes-Gesellschaft. Praxis-Leitlinien der Deutschen Diabetes-Gesellschaft [in German]. Diabetes und Stoffwechsel 2002; 11: 9-13
29. Beale S, Bagust A, Shearer A, et al. Cost-effectiveness of rosiglitazone combination for the treatment of type 2 diabetes in the UK. Pharmacoeconomics 2006; 24 (suppl. 1): 21-34
30. Kulzer B, Hermanns N. Mehr Diabetes Selbstmanagement Typ 2: Ein neues Schulungs- und Behandlungsprogramm für Menschen mit nicht- insulinpflichtigem Typ-2-Diabetes [in German]. Praxis der Klinischen Verhaltensmedizin und Rehabilitation 2001; 54:1 29-136
31. Hannover Consensus Group. German recommendation on health economic evaluation studies. Revised version of the Hannover consensus. Med Klin 2000; 95: 52-5
32. Raftery J. NICE: faster access to modern medicine? Analysis of guidance on health technologies BMJ 2001; 323: 1300-3
33. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for Economic Evaluation of Health Care Programs. Oxford: Oxford University Press; 1997
34. Gozzoli V, Palmer AJ, Brandt A, et al. Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients. Dtsch Med Wochenschr 2000; 125: 1154-9
35. Neeser K, Lubben G, Siebert U, et al. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. Pharmacoeconomics 2004; 22: 321-41
36. Hällsten K, Virtanen KA,Lonnqvist F, et al.Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002; 51: 3479-85
37. Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003; 52: 283-90
38. Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-9
39. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996
40. Drummond MF, O'Brien B, Stoddart GL, Torrance GW, editors. Cost analysis. In: Methods for economic evaluation of health care programs 2 ed. Oxford: Oxford University Press; 1997